Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012
Impact of blockers of AT1 receptors to angiotensin II on endothelium vasoregulating function in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
Clinical significance of angiotensin converting enzyme (ACE) activity in sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 384s Year: 2001
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Cardiohemodynamics changes in COPD patients while using blockers of AT1 receptors to angiotensin II Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006
Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001
A population-based study of statin, ARB, and ACE inhibitor use on pneumonia-related outcomes Source: Annual Congress 2011 - Severity, comorbidities and outcomes in community-acquired pneumonia Year: 2011
Effect of angiotensin converting enzyme (ACE) gene polymorphism on diaphragmatic endurance in neonates Source: Annual Congress 2008 - Neonatal intensive care: ventilation and beyond Year: 2008
Angiotensin-converting enzyme 2 expression is not induced by the renin–angiotensin system in the lung Source: ERJ Open Res, 6 (4) 00402-2020; 10.1183/23120541.00402-2020 Year: 2020
Association between antacid proton pump inhibitors and histamine 2 receptor antagonists) and incidence of lung cancer: a population-based cohort analysis Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The effect of angiotension converting enzyme inhibitors on the production of TGF-β from fibroblast Source: Eur Respir J 2006; 28: Suppl. 50, 227s Year: 2006
Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006
Bronchial reactivity for histamine and serum angiotensin converting enzyme (sACE) activity in sarcoidosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 669s Year: 2004
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal Source: International Congress 2017 – PAH and CTEPH Year: 2017
Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Source: Eur Respir J 2006; 28: 670 Year: 2006
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia Source: Eur Respir J 2008; 31: 611-617 Year: 2008